会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明授权
    • Administration of resveratrol to prevent or treat restenosis following coronary intervention
    • 管理白藜芦醇以预防或治疗冠状动脉介入后的再狭窄
    • US06211247B1
    • 2001-04-03
    • US09434208
    • 1999-11-04
    • David William Goodman
    • David William Goodman
    • A01N3108
    • A61K31/05
    • A method for preventing or treating restenosis and for preventing the recurrence or progression of coronary heart disease is provided. The method involves administration of a selected active agent to a patient following coronary intervention, e.g., coronary artery bypass surgery, endarterectomy, heart transplantation, heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting. The active agent comprises cis-resveratrol, trans-resveratrol, a mixture thereof, or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof. Administration may be oral, parenteral, or the like. Pharmaceutical compositions for use in conjunction with the therapeutic method are also provided.
    • 提供了预防或治疗再狭窄和预防冠心病复发或进展的方法。 该方法包括在冠状动脉介入术(例如冠状动脉旁路手术,内膜切除术,心脏移植,心脏球囊血管成形术,动脉粥样硬化切除术,激光消融或血管内支架置入术)之后向患者施用选定的活性剂。 活性剂包括顺式白藜芦醇,反式白藜芦醇,其混合物或其药理学上可接受的盐,酯,酰胺,前药或类似物。 给药可以是口服,肠胃外等。 还提供了与治疗方法结合使用的药物组合物。
    • 22. 发明授权
    • Administration of resveratrol to prevent or treat restenosis following
coronary intervention
    • 管理白藜芦醇以预防或治疗冠状动脉介入后的再狭窄
    • US6022901A
    • 2000-02-08
    • US78300
    • 1998-05-13
    • David William Goodman
    • David William Goodman
    • A61K31/05A61P9/10A01N31/08
    • A61K31/05
    • A method for preventing or treating restenosis and for preventing the recurrence or progression of coronary heart disease is provided. The method involves administration of a selected active agent to a patient following coronary intervention, e.g., coronary artery bypass surgery, endarterectomy, heart transplantation, heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting. The active agent comprises cis-resveratrol, trans-resveratrol, a mixture thereof, or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof. Administration may be oral, parenteral, or the like. Pharmaceutical compositions for use in conjunction with the therapeutic method are also provided.
    • 提供了预防或治疗再狭窄和预防冠心病复发或进展的方法。 该方法包括在冠状动脉介入术(例如冠状动脉旁路手术,内膜切除术,心脏移植,心脏球囊血管成形术,动脉粥样硬化切除术,激光消融或血管内支架置入术)之后向患者施用选定的活性剂。 活性剂包括顺式白藜芦醇,反式白藜芦醇,其混合物或其药理学上可接受的盐,酯,酰胺,前药或类似物。 给药可以是口服,肠胃外等。 还提供了与治疗方法结合使用的药物组合物。